Leniency vs Settlement in the United Kingdom: Should You Apply for CMA Leniency or Seek a Settlement?

When a company discovers it may have participated in a cartel, the board faces a binary, high-stakes choice: apply to the Competition and Markets Authority (CMA) for leniency, seeking immunity or a significant reduction in penalties, or negotiate a settlement that resolves the matter on agreed terms. The question of leniency vs settlement in the United Kingdom is now more urgent than ever, because the CMA’s revised leniency guidance, finalised on 28 October 2025, tightens the admission and timing requirements that determine which path delivers better protection.

If you can be the first applicant with credible evidence before the CMA has opened an investigation, leniency may deliver full immunity from regulatory fines and criminal prosecution; if timing, board appetite for admissions, or dominant private-claims exposure make early application impractical, settlement offers a more controlled resolution, and this guide sets out exactly how to decide.

The stakes are substantial. CMA fines are calculated on a turnover-based methodology and can reach significant sums. Beyond the regulatory penalty, both routes carry distinct consequences for private damages litigation, director exposure, and corporate reputation. Getting the choice wrong, or delaying it, can lock a company into a worse outcome on every front.

This decision framework is written for in-house counsel, general counsel, CEOs, CFOs, compliance leads, and external competition advisers who need a clear, actionable recommendation rather than an academic overview. It reflects the post-October 2025 CMA guidance landscape and draws on authoritative regulatory and practitioner sources.

Option A: CMA Leniency, What It Is, When It Applies, and Who It Suits

The CMA’s leniency programme incentivises companies and individuals involved in cartel activity to come forward, report the infringement, and cooperate fully with the investigation. In return, the first qualifying applicant can receive total immunity from CMA financial penalties and, for individuals, no-action letters protecting against criminal prosecution under the Enterprise Act 2002. Subsequent applicants may receive significant penalty reductions, though not full immunity. The legal basis sits within the CMA’s published guidance on applications for leniency and no-action in cartel cases, most recently updated in October 2025.

Eligibility and the Marker System

To qualify, a company must be the first to report the cartel activity and provide evidence that the CMA considers sufficiently credible. The CMA operates a marker system: a company can secure its place in the queue by making an initial confidential approach, often via the CMA leniency enquiry line, before submitting full evidence. The marker holds the applicant’s position while it assembles supporting documentation. The revised 2025 CMA leniency guidance tightens expectations around the speed and completeness of these follow-up submissions.

What the CMA Requires

Leniency demands full, truthful admissions of the company’s role in the cartel and production of all relevant evidence. The applicant must maintain continuous cooperation throughout the investigation, which can last years. Oral submissions are permitted at the marker stage, but the CMA expects written, evidenced disclosures promptly thereafter. Privilege strategy is critical: documents created for the purpose of obtaining legal advice remain privileged, but evidence of the underlying infringement does not.

Advantages and Disadvantages

• Advantages: Potential total immunity from CMA fines; protection of individuals from criminal prosecution; ability to control the timing and narrative by coming forward first; favourable positioning if multiple co-conspirators are considering disclosure.
• Disadvantages: Requires full admissions that are difficult to retract; those admissions can be used by claimants in follow-on private damages actions; significant resource commitment (internal investigation, forensic document review, counsel coordination); risk of failure if the CMA determines the application does not meet its criteria, at which point admissions already made may still be in play.

Practical Steps Checklist

• Conduct a rapid internal investigation under privilege to assess the strength of evidence.
• Instruct specialist competition counsel immediately, before any contact with the CMA.
• Implement a document preservation protocol across all relevant jurisdictions.
• Contact the CMA leniency enquiry line confidentially to explore a marker.
• Obtain board-level approval for a full-admission strategy before the marker call.
• Map privilege boundaries to protect legal advice while disclosing factual evidence.

Option B: CMA Settlement, What It Is, When It Applies, and Who It Suits

A CMA settlement is a negotiated resolution in which the company accepts that it has infringed competition law and agrees to a streamlined procedure for determining the penalty. Unlike leniency, settlement does not offer immunity, instead, it typically produces a reduced fine in exchange for cooperation and acceptance of the CMA’s findings, allowing the authority to close the case more quickly. The CMA settlement process can apply to cases under the Competition Act 1998 (Chapter I prohibition and Article 101 TFEU equivalent).

When Settlements Are Available

Settlements are generally available once the CMA has opened an investigation and formed a sufficient view of the infringement. They can also arise in parallel with ongoing proceedings, or when a company that missed the leniency window still wishes to cooperate. The CMA retains discretion over whether to offer settlement discussions, and not every case is suitable.

What a Settlement Agreement Contains

A typical settlement involves the company accepting the CMA’s statement of facts and legal assessment. The wording of admissions can, to some extent, be negotiated, and this is a critical area where skilled drafting can limit exposure to private damages claims. The agreement sets a specific penalty amount and, in return, the company waives certain procedural rights (such as the right to a full oral hearing). Settlement agreement enforceability is contractual: once signed, the agreement binds both parties, and the CMA publishes the outcome.

Advantages and Disadvantages

• Advantages: Greater control over admissions wording; faster resolution than contested proceedings; predictable financial outcome; potentially lower resource burden than a full leniency application; optionality to withdraw from negotiations before agreement is finalised.
• Disadvantages: No possibility of full immunity, a fine will be paid; the discount is typically less than the reduction available through leniency; published settlement decisions provide a roadmap for private damages claimants; limited ability to contest the CMA’s factual findings post-settlement.

Practical Negotiation Checklist

• Assess the CMA’s likely case strength and your evidentiary position before entering talks.
• Identify the admissions the CMA will require and the wording you can accept, draft alternatives.
• Model the financial outcome: compare the likely settlement penalty against a contested decision.
• Map private-claims exposure: ensure settlement wording does not create unnecessary admissions for follow-on litigation.
• Secure board sign-off on the penalty range and admissions scope before substantive negotiations.

Leniency vs Settlement: Side-by-Side Comparison

The table below sets out the core dimensions of the leniency vs settlement United Kingdom decision. Each cell captures the practical position under the CMA’s current framework.

The central trade-off is clear. Leniency offers the possibility of total immunity, an outcome settlement can never deliver, but at the cost of full, irrevocable admissions that materially increase private-claims exposure. Settlement provides a more controlled, less resource-intensive path with negotiable admission wording, but guarantees a financial penalty. For most companies, the right answer depends on whether they can realistically be the first credible leniency applicant and whether the board can tolerate the admission consequences.

Industry observers expect the 2025 guidance changes to sharpen this trade-off further, as the CMA now places greater weight on the speed and completeness of post-marker cooperation, rewarding decisive early movers more generously while implicitly increasing the risk for applicants who hesitate or provide partial evidence.

Dimension-by-Dimension Analysis

Tax Implications: Are CMA Fines Deductible?

Whether a company pursues leniency or settlement, any financial penalty imposed by the CMA is generally not deductible for UK corporation tax purposes. HMRC’s Business Income Manual (BIM38500) establishes that fines and penalties imposed for breaking the law are not allowable deductions against trading profits. This applies equally to competition fines, whether paid under a leniency arrangement (where the applicant receives only a partial reduction rather than full immunity) or under a settlement agreement.

The practical implication is that the full amount of any CMA fine hits the bottom line without tax relief. This makes the difference between immunity (leniency) and a reduced-but-still-substantial penalty (settlement) particularly significant for financial planning.

Cost and Penalty Exposure

The CMA calculates penalties using its published penalty guidance, which employs a turnover-based methodology. The starting point is a percentage of the company’s relevant turnover in the market affected by the infringement, adjusted for the duration of the cartel, aggravating or mitigating factors, and a deterrence uplift where appropriate. Leniency can eliminate this penalty entirely for the first qualifying applicant. Settlement typically yields a negotiated discount from the calculated figure, the size of which depends on the stage at which settlement is reached and the extent of cooperation provided.

Timing and Strategic Trade-Offs

Timing is the single most important variable in the leniency vs settlement decision. A leniency marker must be placed before any co-conspirator approaches the CMA, once the first-mover slot is taken, it cannot be recovered. The 2025 guidance further tightens the window by requiring faster and more complete follow-up after a marker is placed. By contrast, settlement can be pursued at almost any stage of the CMA’s enforcement process, making it the realistic option when the leniency window has closed or when the company only becomes aware of the risk after an investigation is public.

Liability and Private Damages Claims

This is the dimension that most frequently tips the balance for boards evaluating the leniency vs settlement choice. Full admissions made during a leniency application are a matter of record and can be relied upon by private claimants in follow-on damages actions before the Competition Appeal Tribunal or the High Court. While leniency may eliminate the regulatory fine, it can simultaneously arm claimants with the factual admissions they need to establish liability in a civil claim. Settlement admissions, by contrast, can be negotiated: careful drafting of the statement of facts may limit the usable admissions, though published CMA decisions will still provide claimants with material.

• Leniency: Full admissions are mandatory; private-claims risk is elevated; mitigation strategies include proactive engagement with claimants and contribution claims against co-infringers.
• Settlement: Admissions scope is negotiable; private-claims risk is present but potentially more manageable; protective wording should be a central negotiation objective.

Enforceability and Reversibility

Leniency admissions are, in practical terms, irreversible. Once made, they form part of the CMA’s investigative record and cannot be withdrawn even if the CMA ultimately declines to grant full immunity. Settlement agreements are contractual and binding once signed, but the company retains the option to walk away from negotiations before execution, preserving strategic optionality. Settlement agreement enforceability is generally robust: both parties are bound by the agreed terms, and the CMA will not revisit the penalty absent a material breach. However, neither leniency immunity nor a settlement agreement can block private damages claims by third parties, claimants are not parties to these arrangements.

What Changed Under the CMA’s 2025 Guidance

On 28 October 2025, the CMA published its revised guidance on applications for leniency and no-action in cartel cases. The key changes that alter the leniency vs settlement United Kingdom calculus are:

• Tighter post-marker timelines. The CMA now expects faster and more complete follow-up evidence after a marker is placed. Companies that secure a marker but delay substantive disclosure risk losing their position.
• Enhanced admission requirements. The guidance clarifies what constitutes a full and truthful admission, setting a higher bar for the quality and completeness of initial disclosures. Early indications suggest this increases the resource commitment required before contacting the CMA.
• Clearer interaction with private claims. The revised guidance addresses how leniency admissions may be treated in the context of follow-on damages actions, providing greater transparency but also reinforcing the private-claims risk for leniency applicants.
• Updated marker procedures. The marker system has been refined to reward decisive first-movers and to reduce the CMA’s administrative burden from speculative or incomplete applications.

The likely practical effect is that leniency becomes more valuable for companies genuinely positioned to be first with strong evidence, but riskier for those who hesitate or who cannot commit to full admissions quickly. For companies in the latter category, the settlement route may now represent a more realistic path.

Decision Framework: When to Choose Leniency vs Settlement

Choose leniency when you can be the first credible applicant with full evidence; choose settlement when timing, evidence gaps, or private-claims risk make full early admissions impractical.

Choose CMA Leniency (Option A) When:

• You have contemporaneous documentary evidence of the cartel and can be the first to approach the CMA.
• The board has approved a full-admission strategy and understands the private-claims consequences.
• Criminal prosecution of individuals is a realistic risk and no-action letters are essential.
• No other co-conspirator is likely to have approached the CMA already.
• The company can commit the resources for a sustained, multi-year cooperation process.

Choose Settlement (Option B) When:

• The CMA has already opened an investigation and the leniency window is closed or uncertain.
• The board cannot or will not authorise full admissions of cartel involvement.
• Private damages exposure is the dominant commercial risk and you need to control admissions wording.
• Multiple jurisdictions are involved and you need to coordinate a global resolution strategy.
• You want to resolve the regulatory case quickly without the resource burden of full leniency cooperation.

When to Engage a Lawyer for This Decision

The leniency-versus-settlement decision must be made with specialist competition counsel. The following situations should trigger immediate engagement:

• Discovery of potential cartel activity, whether through an internal audit, whistleblower report, or employee departure, before any contact with the CMA or any other party.
• CMA dawn raid or information request, legal privilege and preservation obligations activate immediately; counsel must be on-site or available within hours.
• Receipt of a claim letter or damages action from a customer, competitor, or class-action representative alleging cartel harm.
• Board-level discussion about self-reporting, counsel must advise on privilege, marker strategy, and the admission consequences before any board resolution is passed.
• Contact from a co-conspirator or industry participant suggesting that another party may be approaching the CMA, this compresses the leniency timeline to days or hours.

In the first 48 hours, your counsel should be asked to advise on: document preservation protocols, whether a leniency marker is viable and advisable, privilege mapping across all relevant documents and communications, criminal risk assessment for individuals, and the sequencing of any client statements or internal interviews.

Sources

1. GOV.UK, Applications for Leniency and No-Action in Cartel Cases
2. CMA Leniency Guidance (PDF, October 2025)
3. CMA Penalty Calculation Guidance (PDF)
4. HMRC Business Income Manual, BIM38500: Fines and Penalties
5. Ashurst, The Winner Takes It All? CMA Updates Leniency Policy
6. Cooley LLP, First Mover Advantage: The UK CMA’s Updated Leniency Guidance
7. Law Society, New Leniency Guidance from the CMA
8. Law360, CMA Tightens Leniency Rules for Cartel Whistleblowers